Haijun Sun, formerly of GlaxoSmithKline Plc, has joined ONA Therapeutics SL as chief scientific officer. Based in Spain, ONA is developing treatments for cancer that target lipid metabolism. At GSK, Dr Sun was head of antibody pharmacology where he led a team of assay biologists and immunologists advancing antibody discovery programmes in oncology and inflammatory, neurological and infectious diseases.
ONA Therapeutics announced the appointment on 21 October 2021.
Copyright 2021 Evernow Publishing Ltd